Novo working up a weekly insulin; Zafgen embarks on a rare disease trial;

@FierceBiotech: Hemispherx to test FDA-rejected drug, other candidates against Ebola. FierceBiotech Research story | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). More | Follow @JohnCFierce

@DamianFierce: And now the @FierceMedDev Fierce 15, featuring therapeutic apps, next-gen valves and a light-based hearing aid. Report from FierceMedicalDevices | Follow @DamianFierce

@EmilyMFierce: Global Survey Says We're Eating Better, But Our Diet Is Still Unsustainable. National Geographic story | Follow @EmilyMFierce

> Novo Nordisk ($NVO) and its expansive diabetes R&D operation are in the early stages of development with a once-weekly insulin, a lucrative prospect years away from the market. News

> Zafgen ($ZFGN) has kicked off a Phase III trial of its obesity drug beloranib in Prader-Willi syndrome, a rare genetic disease that results in unrelenting hunger. More

Medical Device News

@FierceMedDev: We've compiled the 15 fiercest med tech companies. Check out FierceMedicalDevices' Fierce 15. Special Report | Follow @FierceMedDev

@MichaelGFierce: RT @EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. Report from FierceBiotechResearch | Follow @MichaelGFierce

@VarunSaxena2: Med tech attorneys say FDA ramping up monitoring of device promotion. Editor's Corner | Follow @VarunSaxena2

@EmilyWFierce: Babies tune out sounds that don't exist in mother's native tongue, form "library of sounds" in brain. Story from Wired | Follow @EmilyWFierce

> Endo to settle remaining claims over vaginal mesh products. Article

> Developer of eye test for Alzheimer's raises $15M in VC round. News

Pharma News

@FiercePharma: Report: Indian government to take legal action over drug quality paper. FiercePharmaManufacturing item | Follow @FiercePharma

@TracyStaton: ICYMI: Who are the fiercest companies in biotech these days? Check out @FierceBiotech's latest Fierce 15. Special Report | Follow @TracyStaton

@CarlyHFierce: Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story via FiercePharmaMarketing | Follow @CarlyHFierce

> Orphan drugs may be pricey, but payers are barely balking. Article

> FDA slaps Valeant with a warning letter. Will Allergan slap it, too? More

Drug Delivery News

> Projection: Implantable drug delivery market to reach $21.1B by 2018. Item

> Which vehicle works best? High-speed testing gives drug delivery a boost. Story

> Alnylam launches study to support its rare disease candidate ALN-AS1. More

> Allergan's drug-delivering eye implant gets expanded indication from FDA. News

> Detoxified anthrax used to deliver cancer drugs within cells. Article

Diagnostics News

> Thermo Fisher has made universal companion Dx development an official trend. Report

> Autism diagnosis could become clearer with sound/sight response screening. More

> Japan approves Infraredx's intravascular ultrasound Dx imaging device. Article

> Trinity Biotech expects FDA submission in early 2015 for heart failure Dx. Story

> J&J, others join $6.5M funding round for U.K. liquid biopsy company. Item

Pharma Marketing News

> Pfizer DTC message: Hey guys, women say it's cool to take Viagra. Story

> Survey: No need to worry about sky-high prices for orphan drugs. Item

> Sunshine fact: $3.5B + 546,000 docs equals one unwieldy database. Report

> Sucampo's Amitiza targets 45-plus women with belly-as-balloon DTC ads. Article

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.